BCRX vs PHVS: How BioCryst Pharmaceuticals and Pharvaris Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and PHVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and PHVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).

Full BCRX guide

Pharvaris N.V. is a Dutch biopharmaceutical company headquartered in Leiden and listed on Nasdaq as PHVS. It works on one disease: hereditary angioedema (HAE), a rare genetic condition in which uncontrolled bradykinin signaling causes sudden, unpredictable and sometimes life-threatening swelling attacks. Its lead candidate, deucrictibant, is a small-molecule oral bradykinin B2 receptor antagonist developed in two formulations from the same molecule: an immediate-release (IR) capsule for treating attacks as they happen, and an extended-release (XR) tablet for preventing them. The company has no approved products and therefore no product revenue, so the income statement is essentially research spending funded by equity raises.

Full PHVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
• PHVS drivers: The deucrictibant IR filing under FDA review; The CHAPTER-3 prophylaxis readout.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard. For PHVS, the concentration risk is close to total: essentially all of the value sits in one molecule, and a complete response letter, a manufacturing or inspection issue, or a safety signal in longer follow-up would hit both indications at once.

Pick BCRX if you believe its drivers more; PHVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and PHVS guides.

BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.

PHVS. There is no revenue multiple to work with here, because there is no revenue: the valuation is a discounted view of what deucrictibant might sell if approved in both on-demand and prophylactic HAE. The financial statements are reported in euros while the shares trade in dollars, so the cash figure and the market cap are not directly comparable without converting. Second-quarter 2026 results were scheduled for release on August 19, 2026, after the figures above.

Headline figures (approximate, JUNE 2026): BCRX shows revenue (ttm) ~$630M, q1 2026 total revenue ~$156M, q1 2026 orladeyo revenue ~$148M (up ~11% YoY), 2026 orladeyo guidance ~$625M to $645M; PHVS shows product revenue None. No approved products yet, cash and equivalents ~247 million euros at March 31, 2026, plus a ~$132 million follow-on closed after quarter end, r&d expense ~30.2 million euros in Q1 2026 (vs ~30.9 million a year earlier), net loss ~39.2 million euros in Q1 2026 (~0.60 euros per share).

BCRX and PHVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCRX and PHVS exposure against your real portfolio. It is not an investment adviser.